[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 18 of about 18
1. Busch TM, Hahn SM, Wileyto EP, Koch CJ, Fraker DL, Zhang P, Putt M, Gleason K, Shin DB, Emanuele MJ, Jenkins K, Glatstein E, Evans SM: Hypoxia and Photofrin uptake in the intraperitoneal carcinomatosis and sarcomatosis of photodynamic therapy patients. Clin Cancer Res; 2004 Jul 15;10(14):4630-8
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia and Photofrin uptake in the intraperitoneal carcinomatosis and sarcomatosis of photodynamic therapy patients.
  • PURPOSE: Response to photodynamic therapy depends on adequate tumor oxygenation as well as sufficient accumulation of photosensitizer in the tumor.
  • The goal of this study was to investigate the presence of hypoxia and retention of the photosensitizer Photofrin in the tumors of patients with intra-abdominal carcinomatosis or sarcomatosis.
  • EXPERIMENTAL DESIGN: Tumor nodules from 10 patients were studied.
  • In nine of these patients, hypoxia was identified in histological sections of biopsied tumor after administration of the hypoxia marker 2-(2-nitroimidazol-1[H]-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide (EF5).
  • In separate tumor nodules from 10 patients, Photofrin uptake was measured by fluorescence after tissue solubilization.
  • RESULTS: Hypoxia existed in the tumors of five patients, with three of these patients demonstrating at least one severely hypoxic nodule.
  • An association between tumor size and hypoxia was not evident because some tumor nodules as small as approximately 2 mm in diameter were severely hypoxic.
  • However, even these tumor nodules contained vascular networks.
  • Three patients with severely hypoxic tumor nodules exhibited moderate levels of Photofrin uptake of 3.9 +/- 0.4 to 3.9 +/- 0.5 ng/mg (mean +/- SE).
  • The four patients with tumors of physiological oxygenation did not consistently exhibit high tumor concentrations of Photofrin: mean +/- SE drug uptake among these patients ranged from 0.6 +/- 0.8 to 5.8 +/- 0.5 ng/mg.
  • CONCLUSIONS: Carcinomatosis or sarcomatosis of the i.p. cavity may exhibit severe tumor hypoxia.
  • Photofrin accumulation in tumors varied by a factor of approximately 10x among all patients, and, on average, those with severe hypoxia in at least one nodule did not demonstrate poor Photofrin uptake in separate tumor samples.
  • These data emphasize the need for reconsideration of the generally accepted paradigm of small tumor size, good oxygenation, and good drug delivery because this may vary on an individual tumor basis.
  • [MeSH-minor] Appendiceal Neoplasms / metabolism. Appendiceal Neoplasms / pathology. Appendiceal Neoplasms / therapy. Benzimidazoles / chemistry. Binding, Competitive / drug effects. Carbocyanines / chemistry. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. Colonic Neoplasms / therapy. Female. Gastrointestinal Stromal Tumors / metabolism. Gastrointestinal Stromal Tumors / pathology. Gastrointestinal Stromal Tumors / therapy. Humans. Hydrocarbons, Fluorinated / chemistry. Hydrocarbons, Fluorinated / metabolism. In Vitro Techniques. Intestine, Small / metabolism. Intestine, Small / pathology. Male. Microscopy, Fluorescence. Oxygen / pharmacology. Photochemotherapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15269134.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA75285; United States / NCI NIH HHS / CA / CA85831; United States / NCI NIH HHS / CA / CA87971; United States / NCRR NIH HHS / RR / M01-RR0040
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide; 0 / Benzimidazoles; 0 / Carbocyanines; 0 / Hydrocarbons, Fluorinated; 0 / cyanine dye 3; 23491-52-3 / HOE 33342; 30DKA3Q1HL / Etanidazole; 97067-70-4 / Dihematoporphyrin Ether; S88TT14065 / Oxygen
  •  go-up   go-down


2. Rossi CR, Deraco M, De Simone M, Mocellin S, Pilati P, Foletto M, Cavaliere F, Kusamura S, Gronchi A, Lise M: Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients. Cancer; 2004 May 1;100(9):1943-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients.
  • BACKGROUND: Abdominal sarcomatosis is a rare nosologic entity with a poor prognosis.
  • After a Phase I study on cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy (HIIC), the authors reported the results of the treatment of 60 patients using this novel multimodal approach.
  • METHODS: Twenty-nine patients had multifocal primary disease and 31 patients had recurrent abdominal sarcoma.
  • Tumor histology was represented by visceral (n = 26 [43%]) and retroperitoneal (n = 34 [57%]) sarcoma.
  • All patients underwent cytoreductive surgery (with no or minimal residual disease) and 90-minute HIIC with doxorubicin (15.25 mg/L of perfusate) and cisplatin (43 mg/L).
  • The clinical outcome and the prognostic value of 11 clinicopathologic variables were analyzed.
  • The median time to local disease progression and the median overall survival were 22 months and 34 months, respectively.
  • Using multivariate analysis, histologic grading and completeness of surgical cytoreduction predicted patient prognosis, indicating that both local progression-free and overall survival were affected significantly by tumor aggressiveness and local disease control.
  • CONCLUSIONS: Although these results were encouraging, there was no definitive conclusion reached regarding the therapeutic activity of this locoregional treatment.
  • In the absence of effective systemic agents, the therapeutic potential of cytoreductive surgery plus HIIC should be explored further in comparative trials.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Peritoneal Neoplasms / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / mortality. Abdominal Neoplasms / pathology. Abdominal Neoplasms / surgery. Adolescent. Adult. Aged. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Intraoperative Care / methods. Laparotomy / methods. Male. Middle Aged. Multivariate Analysis. Prospective Studies. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15112276.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. Hahn SM, Fraker DL, Mick R, Metz J, Busch TM, Smith D, Zhu T, Rodriguez C, Dimofte A, Spitz F, Putt M, Rubin SC, Menon C, Wang HW, Shin D, Yodh A, Glatstein E: A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis. Clin Cancer Res; 2006 Apr 15;12(8):2517-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis.
  • PURPOSE: A previous phase I trial of i.p. photodynamic therapy established the maximally tolerated dose of Photofrin (Axcan Pharma, Birmingham, AL)-mediated photodynamic therapy and showed encouraging efficacy.
  • The primary objectives of this phase II study were to determine the efficacy and toxicities of i.p. photodynamic therapy in patients with peritoneal carcinomatosis and sarcomatosis.
  • The outcomes of interest were (a) complete response, (b) failure-free survival time, and (c) overall survival time.
  • Photosensitizer levels in tumor and normal tissues were measured.
  • RESULTS: One hundred patients were enrolled into one of three strata (33 ovarian, 37 gastrointestinal, and 30 sarcoma).
  • Twenty-nine patients did not receive light treatment.
  • All 100 patients had progressed by the time of statistical analysis.
  • CONCLUSIONS: Intraperitoneal Photofrin-mediated photodynamic therapy is feasible but does not lead to significant objective complete responses or long-term tumor control.
  • Heterogeneity in photosensitizer uptake and tumor oxygenation, lack of tumor specificity for photosensitizer uptake, and the heterogeneity in tissue optical properties may account for the lack of efficacy observed.
  • [MeSH-major] Carcinoma / drug therapy. Dihematoporphyrin Ether / therapeutic use. Peritoneal Neoplasms / drug therapy. Photochemotherapy / methods. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Diarrhea / chemically induced. Edema / chemically induced. Female. Follow-Up Studies. Humans. Male. Middle Aged. Sunburn / etiology. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16638861.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA087971
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


Advertisement
4. Rossi CR, Foletto M, Mocellin S, Pilati P, De SM, Deraco M, Cavaliere F, Palatini P, Guasti F, Scalerta R, Lise M: Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study. Cancer; 2002 Jan 15;94(2):492-9
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study.
  • BACKGROUND: Hyperthermic intraperitoneal intraoperative chemotherapy (HIIC) combined with cytoreductive surgery (CS) has been proposed as a new multimodal treatment mainly for carcinomatosis of gastrointestinal origin.
  • To evaluate whether this regimen could be used for other tumor types, the authors conducted a Phase I study on HIIC with doxorubicin and cisplatin in patients with peritoneal carcinomatosis or sarcomatosis.
  • PATIENTS AND METHODS: Thirty-one patients with peritoneal carcinomatosis or sarcomatosis (PCS) were enrolled for the study.
  • After completion of CS, HIIC was administered with drug doses that were increased for each consecutive cohort following a three-patient cohort scheme.
  • Drug pharmacokinetics and procedure costs also were analyzed.
  • RESULTS: After CS, residual tumors were not present or measured less than or equal to 3 mm (in dimension) in all cases.
  • The perfusate/plasma area under the curve ratios were favorable for both drugs, at 162+/-113 and 20.6+/-6.0, respectively, for doxorubicin and cisplatin.
  • Doxorubicin levels in the peritoneum were higher than in tumor or normal tissue samples.
  • Findings at cost analysis showed that the length of stay in the operation room and intensive care unit were the major cost drivers.
  • CONCLUSIONS: Cytoreductive surgery combined with HIIC is an expensive but feasible therapeutic approach for locally advanced abdominal tumors.
  • Because our preliminary findings for local disease control are encouraging, a Phase II study is now advisable to verify the activity of this promising treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / therapy. Hyperthermia, Induced. Peritoneal Neoplasms / therapy. Sarcoma / therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Costs and Cost Analysis. Doxorubicin / administration & dosage. Female. Humans. Infusions, Parenteral. Intraoperative Care. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11900234.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Griffin GM, Zhu T, Solonenko M, Del Piero F, Kapakin A, Busch TM, Yodh A, Polin G, Bauer T, Fraker D, Hahn SM: Preclinical evaluation of motexafin lutetium-mediated intraperitoneal photodynamic therapy in a canine model. Clin Cancer Res; 2001 Feb;7(2):374-81
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical evaluation of motexafin lutetium-mediated intraperitoneal photodynamic therapy in a canine model.
  • Intraperitoneal photodynamic therapy (IP PDT) is an experimental cancer treatment in clinical development for the treatment of peritoneal carcinomatosis and sarcomatosis.
  • A canine study of motexafin lutetium (Lu-Tex)-mediated IP PDT was performed to evaluate normal tissue toxicities of this treatment in the presence and absence of a bowel resection and to assess the feasibility of measuring Lu-Tex fluorescence in abdominal tissues.
  • Laparoscopy was performed 7-10 days after the procedure to assess acute toxicities.
  • In situ fluorescence spectra were obtained from various abdominal tissues before and after light delivery using a fiber array probe with fixed-source detector distances.
  • Lu-Tex-mediated IP PDT was well tolerated at the doses of drug and light studied.
  • Bowel toxicity was not observed in animals treated with a bowel resection before PDT.
  • Mild transient liver function test abnormalities without associated clinical sequelae were observed.
  • Analysis of the fluorescence spectra from intra-abdominal tissues suggests that measurements of Lu-Tex in situ are feasible and may provide a way of assessing photosensitizer concentration in vivo without the need for a biopsy.
  • [MeSH-minor] Abdomen / pathology. Animals. Dogs. Dose-Response Relationship, Drug. Drug Evaluation, Preclinical. Injections, Intraperitoneal. Kidney / drug effects. Kidney / pathology. Laparoscopy. Necrosis. Neoplasms / drug therapy. Neoplasms / pathology. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11234893.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Metalloporphyrins; 0 / Photosensitizing Agents; 0A85BJ22L6 / motexafin lutetium; 6433A42F4F / motexafin gadolinium
  •  go-up   go-down


6. Kusamura S, Younan R, Baratti D, Costanzo P, Favaro M, Gavazzi C, Deraco M: Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer; 2006 Mar 1;106(5):1144-53
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique.
  • BACKGROUND: The purpose of this prospective Phase II study was to analyze morbidity and mortality of cytoreductive surgery (CRS) and intraperitoneal hyperthermic perfusion (IPHP) in the treatment of peritoneal surface malignancies.
  • METHODS: A total of 205 patients (50 with peritoneal mesothelioma, 49 with pseudomyxoma peritonei, 41 with ovarian cancer, 32 with abdominal sarcomatosis, 13 with colon cancer, 12 with gastric cancer, and 8 with carcinomatosis from other origins) underwent 209 consecutive procedures.
  • Four patients underwent the intervention twice because of disease relapse.
  • IPHP through the closed abdomen technique was conducted with a preheated (42.5 degrees C) perfusate containing cisplatin + mitomycin C or cisplatin + doxorubicin.
  • On logistic regression model multivariate analysis, extent of cytoreduction (odds ratio [OR], 2.88; 95% confidence interval [CI], 1.29-6.40) and dose of cisplatin for IPHP > or = 240 mg (OR, 3.13; 95% CI, 1.24-7.90) were independent risk factors for major morbidity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hyperthermia, Induced. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Humans. Infusions, Parenteral. Male. Middle Aged. Mitomycin / administration & dosage. Morbidity. Neoplasm Recurrence, Local. Treatment Outcome

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16456817.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Bonvalot S, Cavalcanti A, Le PĂ©choux C, Terrier P, Vanel D, Blay JY, Le Cesne A, Elias D: Randomized trial of cytoreduction followed by intraperitoneal chemotherapy versus cytoreduction alone in patients with peritoneal sarcomatosis. Eur J Surg Oncol; 2005 Oct;31(8):917-23
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of cytoreduction followed by intraperitoneal chemotherapy versus cytoreduction alone in patients with peritoneal sarcomatosis.
  • PURPOSE: In order to decrease loco-regional relapse after complete resection of peritoneal sarcomatosis (PS), the role of intraperitoneal chemotherapy (IPEC) was prospectively evaluated.
  • METHODS: Patients (pts) with completely resected PS were randomized between adjunction of IPEC or not.
  • IPEC consisted of doxorubicin, 0.1mg/kg and cisplatin, 15 mg/m(2) per day for 5 consecutive days.
  • Primary endpoint was survival, measured as time from randomization to death.
  • The scheduled number of patients needed was 40 in order to detect a minimal increase of 40% overall survival with the adjunction of IPEC with a power of 80%.
  • RESULTS: Thirty-eight consecutive pts have been randomized, 19 in each group.
  • Ratio of retroperitoneal (RPS) and visceral (VS) sarcomatosis were 9/10 and 6/13 in IPEC- and IPEC+ group, respectively.
  • There were no toxic deaths and morbidity was similar in both groups (four pts in each group).
  • The median local relapse-free, metastatic relapse-free survival and overall survival were identical in both groups (12.5, 18 and 29 months, respectively), with no difference between RPS and VS sarcomatosis.
  • CONCLUSION: Administration of IPEC after a macroscopically complete surgery did not allow to increase greatly the outcome of pts.
  • Complete surgery remains the cornerstone of the treatment of patients with sarcomatosis with best results for low grade sarcomatosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Peritoneal Neoplasms / surgery. Sarcoma / surgery
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Chemotherapy, Cancer, Regional Perfusion / methods. Cisplatin / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Electrosurgery. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Prospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15975759.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Lim SJ, Cormier JN, Feig BW, Mansfield PF, Benjamin RS, Griffin JR, Chase JL, Pisters PW, Pollock RE, Hunt KK: Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis. Ann Surg Oncol; 2007 Aug;14(8):2309-18
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis.
  • BACKGROUND: Treatment of peritoneal recurrence following surgical resection of intra-abdominal sarcomas presents a significant challenge to clinicians.
  • Historically, treatment with systemic chemotherapy has been ineffective and surgical resection alone has not been durable.
  • We prospectively evaluated the feasibility of cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin (CDDP) alone or in combination with mitoxantrone (MITOX) for the treatment of sarcomatosis.
  • Eligible patients with evidence of sarcomatosis underwent cytoreductive surgery followed by HIPEC.
  • In the first trial, CDDP dosing was established as 90 mg/m2 with a perfusate time of 90 minutes and temperature of 41 degrees C.
  • As expected, QOL scores at 6-8 weeks following HIPEC were 15-25% lower than the baseline scores; however, they returned to baseline at 3-6 months.
  • CONCLUSIONS: Although the HIPEC technique is feasible for patients with sarcomatosis, it is associated with significant toxicity and limited clinical benefit.
  • [MeSH-major] Antineoplastic Agents / toxicity. Cisplatin / toxicity. Hyperthermia, Induced. Mitoxantrone / toxicity. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Sarcoma / drug therapy. Sarcoma / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Cancer, Regional Perfusion / methods. Clinical Trials, Phase I as Topic. Combined Modality Therapy. Disease-Free Survival. Drug Therapy, Combination. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prospective Studies. Quality of Life. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17541691.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BZ114NVM5P / Mitoxantrone; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Gonlugur T, Sapmaz F, Katrancioglu O, Gonlugur U, Elagoz S: Pulmonary lymphangitic sarcomatosis and a review of the literature. Clin Exp Metastasis; 2009;26(5):399-402
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary lymphangitic sarcomatosis and a review of the literature.
  • Intrapulmonary spread of a sarcoma via lymphatics is a rare cause of death in a young adult.
  • A 31-year old man was admitted to our hospital complaining of dyspnea and malaise of 2 months' duration.
  • Thoracic CT-scans demonstrated mediastinal lymphadenopathy, thickening of interlobular septa, polygonal lines, and thickening of bronchovascular bundles.
  • Pulmonary lymphangitic sarcomatosis is a rare but important manifestation of an angiosarcoma.
  • Optimal treatment of these patients is not well defined, but a trial of chemotherapy may be warranted.
  • [MeSH-major] Lymphatic Diseases / diagnosis. Lymphatic Diseases / therapy. Sarcoma / diagnosis. Sarcoma / therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Cytoplasm / metabolism. Diagnosis, Differential. Fatal Outcome. Humans. Male. Pelvic Neoplasms / diagnosis. Radiography, Thoracic / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 1987 May;111(5):459-63 [3105516.001]
  • [Cites] Radiology. 1988 Mar;166(3):705-9 [3340765.001]
  • [Cites] Arch Pathol Lab Med. 1986 Feb;110(2):112-5 [3753842.001]
  • [Cites] AJR Am J Roentgenol. 1992 Jun;158(6):1217-22 [1590110.001]
  • [Cites] Chest. 1993 Mar;103(3):967-8 [8449110.001]
  • [Cites] Chest. 1976 Jan;69(1):106-8 [1244262.001]
  • [Cites] Jpn J Clin Oncol. 2000 Jan;30(1):37-9 [10770568.001]
  • [Cites] Cancer. 1974 Jun;33(6):1558-63 [4834152.001]
  • [Cites] Chest. 1972 Aug;62(2):179-87 [5050223.001]
  • [Cites] Chest. 1992 Oct;102(4):1113-7 [1327663.001]
  • [Cites] AJR Am J Roentgenol. 1985 Sep;145(3):505-10 [3927666.001]
  • [Cites] Arch Pathol Lab Med. 2007 Jun;131(6):970-3 [17550329.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):825-8 [15350381.001]
  • [Cites] Intern Med. 2007;46(8):491-4 [17443041.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):229-32 [10623714.001]
  • [Cites] J Thorac Imaging. 1985 Dec;1(1):54-64 [3843414.001]
  • [Cites] Respiration. 1998;65(5):406-10 [9782226.001]
  • [Cites] Acta Otolaryngol Suppl. 2004 Oct;(554):71-3 [15513516.001]
  • [Cites] AJR Am J Roentgenol. 1995 Jul;165(1):49-52 [7785630.001]
  • [Cites] Int J Gynecol Cancer. 2002 Mar-Apr;12 (2):208-13 [11975682.001]
  • (PMID = 18506585.001).
  • [ISSN] 1573-7276
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


10. Charney SC, Bergman PJ, McKnight JA, Farrelly J, Novosad CA, Leibman NF, Camps-Palau MA: Evaluation of intracavitary mitoxantrone and carboplatin for treatment of carcinomatosis, sarcomatosis and mesothelioma, with or without malignant effusions: A retrospective analysis of 12 cases (1997-2002)*. Vet Comp Oncol; 2005 Dec;3(4):171-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of intracavitary mitoxantrone and carboplatin for treatment of carcinomatosis, sarcomatosis and mesothelioma, with or without malignant effusions: A retrospective analysis of 12 cases (1997-2002)*.
  • Abstract Carcinomatosis, sarcomatosis and mesothelioma, with or without malignant effusions, are difficult to treat and generally carry a poor prognosis.
  • The purpose of this study was two-fold; first, to determine the prognosis for dogs with carcinomatosis, sarcomatosis, or mesothelioma, with or without malignant effusions; second, to evaluate the safety and efficacy of treatment with intracavitary (IC) carboplatin and mitoxantrone in dogs with these syndromes.
  • Seven were untreated and 12 were treated with IC chemotherapy (mitoxantrone and/or carboplatin), and multiple factors were analysed for significance with respect to survival time.
  • The median survival time (MST) for untreated dogs was 25 days, whereas the MST for treated dogs was 332 days (Log Rank, P < 0.0001).
  • Treatment with IC chemotherapy was well tolerated.
  • This study suggests that IC chemotherapy with mitoxantrone and/or carboplatin is an effective treatment for dogs with carcinomatosis, sarcomatosis or mesothelioma, with or without malignant effusion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19754772.001).
  • [ISSN] 1476-5829
  • [Journal-full-title] Veterinary and comparative oncology
  • [ISO-abbreviation] Vet Comp Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Pilati P, Rossi CR, Mocellin S, Foletto M, Scagnet B, Pasetto L, Lise M: Multimodal treatment of peritoneal carcinomatosis and sarcomatosis. Eur J Surg Oncol; 2001 Mar;27(2):125-34
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodal treatment of peritoneal carcinomatosis and sarcomatosis.
  • Peritoneal carcinomatosis and sarcomatosis (PCS) are short-term fatal conditions amenable only to palliative treatment.
  • They are generally considered as a systemic disease at clinical presentation, and are resistant to standard treatments.
  • However, there may be in the natural history a phase of loco-regional tumour spread during which the tumour may still be curable.
  • Surgical treatment alone, or in combination with systemic chemotherapy, has yielded poor results in terms of survival and quality of life.
  • One approach is cytoreductive surgery (CS) combined with the intraperitoneal administration of antiblastic agents.
  • This may diminish any residual tumour following macroscopic excision and may overcome the pharmacokinetic limits of systemic chemotherapy.
  • A further improvement in this multimodal approach may be achieved by the use of hyperthermic intraperitoneal intraoperative chemotherapy (HIIC).
  • However, series reported in the literature are relatively small and heterogeneous, and clinical and technical factors which include the selection of patients, optimal drugs dosage and temperature, evaluation of outcome and costs are still under discussion.
  • [MeSH-major] Carcinoma / therapy. Peritoneal Neoplasms / therapy. Sarcoma / therapy
  • [MeSH-minor] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Humans. Hyperthermia, Induced. Neoadjuvant Therapy. Quality of Life. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Harcourt Publishers Limited.
  • (PMID = 11289746.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 99
  •  go-up   go-down


12. Peixoto Callejo I: Peritoneal solitary fibrous tumour (SFT): long-term survival of recurrent and metastasised SFT treated with cytoreductive surgery and intraperitoneal chemotherapy. Clin Transl Oncol; 2009 Apr;11(4):250-2
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal solitary fibrous tumour (SFT): long-term survival of recurrent and metastasised SFT treated with cytoreductive surgery and intraperitoneal chemotherapy.
  • This study reports a case of a SFT of the peritoneum in a 44-year-old white man that recurred 3 years after the initial surgical removal of the tumour.
  • The patient recurred diffusely, developing a pattern of sarcomatosis and hepatic metastasis and was treated by surgical cytoreduction followed by intraoperative peritoneal hyperthermic chemotherapy (IPHC).
  • Subsequently, he developed pulmonary metastases and was treated with palliative chemotherapy.
  • The patient persisted with recurrent and distant disease, although it was reduced and stabilised, allowing his survival for the last 3 years since the extended surgery.
  • New treatment strategies for a rare disease such as this one have first to be described in order to improve patient follow-up.
  • [MeSH-major] Liver Neoplasms / mortality. Lung Neoplasms / mortality. Neoplasm Recurrence, Local / mortality. Peritoneal Neoplasms / mortality. Peritoneal Neoplasms / therapy. Solitary Fibrous Tumors / mortality. Solitary Fibrous Tumors / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Hyperthermia, Induced. Male. Surgical Procedures, Operative. Survival Rate. Survivors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):727-31 [10622499.001]
  • [Cites] Hum Pathol. 1999 Dec;30(12):1464-73 [10667425.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):543-59 [14567017.001]
  • [Cites] Lung Cancer. 1999 Jan;23 (1):53-60 [10100146.001]
  • [Cites] Arch Pathol Lab Med. 2006 Feb;130(2):213-6 [16454566.001]
  • [Cites] Cancer J Sci Am. 1999 Jan-Feb;5(1):48-51 [10188061.001]
  • [Cites] Ann Diagn Pathol. 1998 Feb;2(1):19-24 [9845719.001]
  • [Cites] Arch Pathol Lab Med. 2004 Apr;128(4):460-2 [15043457.001]
  • (PMID = 19380303.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


13. Vocelka CR, Anderson DL, Crockett GI: Hyperthermic intraoperative intraperitoneal chemotherapy for peritoneal carcinomatosis and sarcomatosis using a cardioplegia heat exchanger and a two-pump system: a case report. Perfusion; 2000 Nov;15(6):549-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperthermic intraoperative intraperitoneal chemotherapy for peritoneal carcinomatosis and sarcomatosis using a cardioplegia heat exchanger and a two-pump system: a case report.
  • A 34-year-old male diagnosed with pseudomyxoma peritoneii presented for an exploratory laparotomy and hyperthermic intraoperative intraperitoneal chemotherapy.
  • A circuit using two roller pumps and a cardioplegia administration set was assembled to deliver the chemotherapy perfusate at a consistent temperature.
  • The authors discuss a case in which this treatment modality was used, describing the perfusionist's role and the circuit design.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma / drug therapy. Carcinoma / surgery. Hyperthermia, Induced / methods. Infusions, Parenteral / instrumentation. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Sarcoma / drug therapy. Sarcoma / surgery
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Intraoperative Care / instrumentation. Intraoperative Care / methods. Male. Omentum / pathology. Splenic Neoplasms / drug therapy. Splenic Neoplasms / secondary. Splenic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11131220.001).
  • [ISSN] 0267-6591
  • [Journal-full-title] Perfusion
  • [ISO-abbreviation] Perfusion
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


14. Rossi CR, Casali P, Kusamura S, Baratti D, Deraco M: The consensus statement on the locoregional treatment of abdominal sarcomatosis. J Surg Oncol; 2008 Sep 15;98(4):291-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The consensus statement on the locoregional treatment of abdominal sarcomatosis.
  • Abdominal sarcomatosis (AS) is a rare condition characterized by soft tissue sarcoma spreading throughout the abdomen, in the absence of extra-abdominal dissemination.
  • Systemic chemotherapy is the standard of care for AS from non-GIST sarcomas, but with an essentially palliative aim and major limitations.
  • Innovative targeted therapies has deeply affected the natural history of GIST, at least in prolonging significantly survival in responsive patients.
  • In this context, the notion that abdominal spread in the lack of extra-peritoneal lesions may typically occur in a number of patients, along with the dismal prognosis generally carried by AS, has prompted a few centers to perform cytoreductive surgery and perioperative intraperitoneal chemotherapy.
  • To date, the rarity of these presentations makes it difficult to evaluate the clinical results and the role of combined local-regional treatment is still a matter of debate.
  • This article presents the results of a group of experts from around the World trying to achieve a consensus statement in AS comprehensive management.
  • A questionnaire was placed on the website of the 5th International Workshop on Peritoneal Surface Malignancy and the experts voted via internet.
  • [MeSH-major] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / surgery. Chemotherapy, Cancer, Regional Perfusion / methods. Hyperthermia, Induced. Sarcoma / drug therapy. Sarcoma / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Consensus. Humans. Infusions, Parenteral. Practice Guidelines as Topic

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18726899.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


15. Baratti D, Pennacchioli E, Kusamura S, Fiore M, Balestra MR, Colombo C, Mingrone E, Gronchi A, Deraco M: Peritoneal sarcomatosis: is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy? Ann Surg Oncol; 2010 Dec;17(12):3220-8
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal sarcomatosis: is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?
  • BACKGROUND: Unlike novel molecular-targeted therapies for metastatic gastrointestinal stromal tumors (GIST), conventional treatments for peritoneal sarcomatosis (PS) are mostly ineffective.
  • As with carcinomatosis of epithelial origin, a rationale base supports an aggressive locoregional treatment of PS, but the use of CRS and HIPEC in this setting is still controversial.
  • We assessed the outcome of clinically and pathologically homogeneous subsets of patients with PS uniformly treated by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
  • After median follow-up of 104 (range, 1-131) months, peritoneal disease progression occurred in 16 patients, distant metastases in 5, and both in 13.
  • CONCLUSIONS: Overall, results of CRS and HIPEC did not compare favorably to those of conventional therapy.
  • In a subgroup analysis, the combined approach did not change GIST and RPLS natural history.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Leiomyosarcoma / therapy. Peritoneal Neoplasms / therapy. Uterine Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Humans. Liposarcoma / classification. Liposarcoma / pathology. Liposarcoma / therapy. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Staging. Prospective Studies. Retroperitoneal Neoplasms / classification. Retroperitoneal Neoplasms / pathology. Retroperitoneal Neoplasms / therapy. Survival Rate. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ann Surg Oncol. 2011 Dec;18 Suppl 3:S327. Alessanrdro, Gronchi [corrected to Gronchi, Alessandro]
  • (PMID = 20585874.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; Retroperitoneal liposarcoma
  •  go-up   go-down


16. Younan R, Kusamura S, Baratti D, Oliva GD, Costanzo P, Favaro M, Gavazzi C, Deraco M: Bowel complications in 203 cases of peritoneal surface malignancies treated with peritonectomy and closed-technique intraperitoneal hyperthermic perfusion. Ann Surg Oncol; 2005 Nov;12(11):910-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bowel complications in 203 cases of peritoneal surface malignancies treated with peritonectomy and closed-technique intraperitoneal hyperthermic perfusion.
  • We analyzed the risk factors for bowel complications with primary anastomoses and the closed technique for IPHP.
  • We retrospectively analyzed this series of patients.
  • Treated pathologies included peritoneal mesothelioma; pseudomyxoma peritonei; colorectal, ovarian, or gastric carcinomatosis; and abdominal sarcomatosis.
  • Only one defunctioning stoma was used.
  • RESULTS: We found a bowel complication rate of 10.8%.
  • On univariate analysis we found a statistically significant association between bowel complications and the following variables: sex, previous systemic chemotherapy status, number of anastomoses ( fewer than two vs. two or more), duration of the procedure (<8.7 vs. >or=8.7 hours), and extent of cytoreduction.
  • After multivariate analysis, male sex (odds ratio [OR], 4.2), no previous systemic chemotherapy (OR, 3.5), and duration of the procedure >or=8.7 hours (OR, 6.3) were considered independent risk factors for bowel complications.
  • CONCLUSIONS: Bowel complications are not increased when primary unprotected anastomoses are performed during peritonectomy and IPHP when the closed technique is used.
  • Male sex, duration of the procedure, and no previous systemic chemotherapy are independent unfavorable risk factors.
  • [MeSH-major] Hyperthermia, Induced. Intestinal Diseases / etiology. Peritoneal Neoplasms / complications. Peritoneal Neoplasms / therapy. Peritoneum / surgery
  • [MeSH-minor] Adult. Aged. Anastomosis, Surgical / adverse effects. Antibiotics, Antineoplastic / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Colon / surgery. Combined Modality Therapy. Female. Gastrectomy. Humans. Intestinal Fistula / etiology. Intestines / surgery. Male. Middle Aged. Multivariate Analysis. Retrospective Studies. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16177862.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic
  •  go-up   go-down


17. Baratti D, Kusamura S, Deraco M: The Fifth International Workshop on Peritoneal Surface Malignancy (Milan, Italy, December 4-6, 2006): methodology of disease-specific consensus. J Surg Oncol; 2008 Sep 15;98(4):258-62
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Fifth International Workshop on Peritoneal Surface Malignancy (Milan, Italy, December 4-6, 2006): methodology of disease-specific consensus.
  • Peritoneal surface malignancies (PSM) have been traditionally regarded as uniformly terminal conditions.
  • The combination of cyto-reductive surgery and perioperative intraperitoneal chemotherapy has changed PSM management from palliation to possible cure.
  • Due to the inherent differences in biological and clinical behavior, the optimal adaptation of comprehensive treatment to each PSM is still a matter of debate.
  • A session of "The Fifth International Workshop on Peritoneal Surface Malignancy" (Milan, Italy, December 4-6, 2006) was committed to reach a consensus pertaining to conceptual and technical aspects of the loco-regional treatment of each PSM.
  • A total of 103 international experts from 17 countries were included in six Working Groups (WG) for each of the following PSM: peritoneal mesothelioma, abdominal sarcomatosis, carcinomatosis of gastric, colo-rectal, appendiceal, and ovarian origin.
  • The main conflicting points (CP) regarding preoperative evaluation, patient eligibility, combined treatment methodology, postoperative follow-up and future investigational perspectives were summarized as a list of multiple-choice questions.
  • A consensus >or=51% of voters favoring one option was reached in 143/160 CP (89.4%).
  • The general treatment guidelines and future investigational perspectives were defined.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Chemotherapy, Cancer, Regional Perfusion / methods. Hyperthermia, Induced. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Consensus. Delphi Technique. Humans. Infusions, Parenteral

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18726888.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 23
  •  go-up   go-down


18. Deraco M, Laterza B, Kusamura S, Baratti D: [Updated treatment of peritoneal carcinomas: a review]. Minerva Chir; 2007 Dec;62(6):459-76
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Updated treatment of peritoneal carcinomas: a review].
  • Peritoneal surface malignancy (PSM) is a clinical entity with an unfavourable prognosis, which characterizes the evolution of neoplastic diseases from the abdominal and/or pelvic organs and could also be the terminal stage of extra-abdominal tumors.
  • Examples of diseases that can spread mainly within the peritoneal cavity are appendiceal tumors, ovarian cancer, colorectal cancer, abdominal sarcomatosis, gastric cancer and peritoneal mesothelioma.
  • The locoregional therapy is defined as the combination of cytoreductive surgery (CRS) and intraperitoneal hyperthermic perfusion (IPHP).
  • The rationale of this combined therapy for PSM is based on the natural history of this clinical entity that remains confined in the peritoneal cavity for most of its natural history.
  • This pattern of spread would seem to indicate the potential usefulness of selectively increasing drug concentration in the tumour-bearing area by direct intraperitoneal chemotherapy instillation.
  • This approach led to these outcomes: the median survival of colorectal carcinoma and ovarian cancer was 32 months; patients with peritoneal mesothelioma showed 57% survival at 5 years, while in patients with appendiceal mucinous tumors and pseudomyxoma peritonei (PMP) the 10 years overall survival was 78%.
  • A significant improvement in survival was associated with hyperthermic intra-peritoneal chemotherapy (HIPEC) in patients with gastric cancer.
  • Considering the constant increasing of diseases treatable with this procedure, more centres should be activated.
  • The establishment of a clear policy and scientific guidelines is mandatory, in order to perform the CRS+HIPEC safely, minimizing treatment-related morbidity and mortality and maximizing the results in terms of survival and quality of life.
  • [MeSH-minor] Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Critical Care. Female. Humans. Hyperthermia, Induced. Infusions, Parenteral. Injections, Intraperitoneal. Male. Nutritional Support. Patient Selection. Postoperative Care. Postoperative Complications. Quality of Life. Risk Factors. Survival Analysis. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18091656.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] ita
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 71
  •  go-up   go-down






Advertisement